Insider Selling: Abeona Therapeutics Inc (NASDAQ:ABEO) Director Sells 4,000 Shares of Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino sold 4,000 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $5.38, for a total transaction of $21,520.00. Following the transaction, the director now owns 64,334 shares of the company’s stock, valued at approximately $346,116.92. This represents a 5.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Mark Alvino also recently made the following trade(s):

• On Tuesday, January 21st, Mark Alvino sold 4,000 shares of Abeona Therapeutics stock. The shares were sold at an average price of $5.10, for a total transaction of $20,400.00.

Abeona Therapeutics Stock Performance

Shares of ABEO stock traded up $0.07 during trading hours on Friday, reaching $5.54. The company had a trading volume of 237,491 shares, compared to its average volume of 302,800. The business has a fifty day moving average price of $5.74 and a 200-day moving average price of $5.72. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The firm has a market cap of $240.82 million, a PE ratio of -2.06 and a beta of 1.46. Abeona Therapeutics Inc has a one year low of $3.05 and a one year high of $9.01.

Hedge Funds Weigh In On Abeona Therapeutics

Several institutional investors have recently bought and sold shares of ABEO. Jane Street Group LLC bought a new position in shares of Abeona Therapeutics during the third quarter valued at approximately $84,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Abeona Therapeutics during the 3rd quarter valued at $151,000. XTX Topco Ltd purchased a new position in Abeona Therapeutics in the 3rd quarter worth $160,000. JPMorgan Chase & Co. raised its stake in Abeona Therapeutics by 74.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock worth $424,000 after acquiring an additional 28,606 shares during the last quarter. Finally, GSA Capital Partners LLP grew its position in Abeona Therapeutics by 54.3% during the 3rd quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock worth $607,000 after purchasing an additional 33,831 shares during the period. Institutional investors own 80.56% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on ABEO. StockNews.com cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $18.00 target price on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Abeona Therapeutics in a research report on Monday, November 25th.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.